Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 27, 2022

Sciwind, SynerK to develop novel therapeutics for liver and metabolic diseases

Clinical-stage biopharmaceutical firm Sciwind Biosciences has signed a research partnership agreement with RNAi therapeutics company SynerK for the joint development of novel therapeutics to treat liver and metabolic diseases.

The companies will discover and develop novel siRNA therapeutics. Credit: günter from Pixabay.